ADAG
Adagene IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$224.65M
P/E Ratio
—
EPS
$-0.38
Beta
0.59
52W High
$4.75
52W Low
$1.30
50-Day MA
$3.75
200-Day MA
$2.66
Dividend Yield
—
Profit Margin
-229.60%
Forward P/E
—
PEG Ratio
—
About Adagene Inc
Adagene Inc., a clinical-stage biopharmaceutical company, is dedicated to the research, development, and production of monoclonal antibody drugs for cancer. The company is headquartered in Suzhou, China.
Fundamentals
| Revenue (TTM) | $7.67M |
| Gross Profit (TTM) | $7.67M |
| EBITDA | $-21.00M |
| Operating Margin | -75.00% |
| Return on Equity | -34.40% |
| Return on Assets | -16.00% |
| Revenue/Share (TTM) | $0.16 |
| Book Value | $0.75 |
| Price-to-Book | 6.36 |
| Price-to-Sales (TTM) | 29.29 |
| EV/Revenue | 20.39 |
| EV/EBITDA | 1.12 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 7333.00% |
| Shares Outstanding | $66.07M |
| Float | $33.88M |
| % Insiders | 21.16% |
| % Institutions | 20.09% |
Historical Volatility
HV 10-Day
89.13%
HV 20-Day
74.90%
HV 30-Day
65.43%
HV 60-Day
83.24%
HV Rank
17.1%
Volatility is currently expanding
Analyst Ratings
Consensus ($9.40 target)
5
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 6/10/2026